This study is testing an experimental treatment called corneal crosslinking (CXL) to help people with eye conditions that make the cornea, the clear front part of the eye, thin and misshapen. This can cause blurry vision. CXL works by putting riboflavin (Vitamin B2) drops on the eye and shining ultraviolet (UVA) light on it, similar to sunlight. This strengthens the cornea and can help stop the eye condition from getting worse.
Participants will be at least 8 years old and have specific eye conditions like keratoconus or ectasia. The study will help find out if CXL can prevent or slow down vision loss. There are two groups in the study: one will receive 18 minutes of UVA light and the other 24 minutes.
- Participants will attend up to 7 office visits over 6 months for eye tests.
- They will receive the CXL treatment during one of these visits.
- Participants cannot be pregnant and must agree to birth control if needed.
How understandable was the trial content above?
Hard to understand
Easy to understand